• blood pressure and heart rate measure in sitting position [ Time Frame: at each visit ]
• IPSS and Quality of Life Score [ Time Frame: at intermediate visit (M1) and at end-point visit(M3) ]
• Maximum flow rate and post voiding residual urine [ Time Frame: at end-point visit(M3) ]
• Spontaneous reported adverse events [ Time Frame: During all the study period ]

To collect under daily practice conditions, clinical data on the changes of sexual function when a new formulation of alfuzosin(Xatral XL® )is administered once daily in patients with lower urinary tract symptoms(LUTS) suggestive of prostatic hypertrophy

Inclusion Criteria:

• male patients suffering from LUTS lasting 6months and over
• male patients aged 50 years old and over who has a continuous active partner

Exclusion Criteria:

• Primary hypogonadism and neuropathy patients
• History of prostate surgery
• Patients with prostate cancer
• History of organ surgery or organ damage in pelvis
• History of myocardiac infarction, stroke, and life threatening arrythmia within last 6 months
• Patients with haematuria caused by other reasons except BPH
• Patients with uncontrolled hypertension in spite of treatment with antihypertensive agents
• History of a malignant tumor within last 5 years
• Patients who are currently controlled with other medication for erectile dysfunction
• Patients who have been administered with androgen or antiandrogen
• Patients who is treated for psychiatric disorder or depression
• Combination with other alpha1-blockers
• Patients previously not improved by an alpha1-blocker treatment
• Known hypersensitivity to the alfuzosin
• History of postural hypotension or syncope
• Hepatic insufficiency
• Unstable angina pectoris

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.